Scorr-Insert
X

Find Novel Immunology Drugs in Preclinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ApoGraft treated stem cells

            Therapeutic Area: Immunology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 21, 2020

            Details:

            Cellect Biotechnology has signed a development agreement with an international consortium to examine the therapeutic effects of ApoGraft treated stem cells on the reduction of pulmonary manifestations caused by COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GP1681

            Therapeutic Area: Immunology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $1.6 million Upfront Cash: Undisclosed

            Deal Type: Funding May 13, 2020

            Details:

            The Phase II SBIR grant is non-dilutive funding from the National Institute of Allergy and Infectious Diseases of the NIH and will advance the research of GP1681.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ST266

            Therapeutic Area: Immunology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Noveome Biotherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 12, 2020

            Details:

            Under the terms of the collaboration, Singota will manufacture Noveome’s ST266 to be used for IV infusion in Phase I and II clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ST266

            Therapeutic Area: Immunology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Commonwealth of Pennsylvania

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Funding May 07, 2020

            Details:

            Funding enables existing clinical trial of its lead product candidate, ST266, to proceed as company joins global response with covid-19 program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Plasma-derived Inter-alpha Inhibitor Proteins therapy

            Therapeutic Area: Immunology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 23, 2020

            Details:

            As part of the agreement, ProThera and Takeda will work together on IND-enabling activities, with development led by Takeda's dedicated Plasma Derived Therapies R&D organization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anandamide

            Therapeutic Area: Immunology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 21, 2020

            Details:

            The study conducted in partnership with Zylö Therapeutics confirmed mice treated with Anandamide (AEA)-loaded particles experienced lesions that regressed in size and severity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TXR-711

            Therapeutic Area: Immunology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 21, 2020

            Details:

            TXR-711 and TXR-712, demonstrated significant efficacy and excellent tolerability in preclinical studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMP761

            Therapeutic Area: Immunology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2020

            Details:

            Using its STEP®-mAb technology, Batavia Biosciences has developed a pharmaceutical-grade, stable CHO cell line that produces significantly high product yields of IMP761.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ruxolitinib

            Therapeutic Area: Immunology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 02, 2020

            Details:

            Novartis plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi for treatment of severe immune overreaction called cytokine storm in COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biotechnology Value Fund

            Deal Size: $102.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing March 12, 2020

            Details:

            The fund will support development of Kymera's lead program IRAK4.

            PharmaCompass